Phone
Address Talkabouturology, Nizhny Novgorod, Russia
Email Talkabouturology@list.ru
                                    Talk about urology

Back to the list

The first oral gonadotropin-releasing hormone (GnRH) receptor antagonist for adults with advanced prostate cancer is now available in clinical practice. Just over a month ago, the FDA approved Relugolix for adults with advanced disease who are candidates for at least 1 year of continuous androgen deprivation therapy

The first oral gonadotropin-releasing hormone (GnRH) receptor antagonist for adults with advanced prostate cancer is now available in clinical practice. Just over a month ago, the FDA approved Relugolix for adults with advanced disease who are candidates for at least 1 year of continuous androgen deprivation therapy 


https://www.schu.cl/urolchi/el-primer-antagonista-oral-de-los-receptores-de-gnrh-entra-en-la-cartera-de-tratamientos-del-cancer-de-prostata-avanzado/?fbclid=IwAR2iZFgyfnVSj03SFuoBtPMY_E8XwRWWRLGU9C9IWCElSgLIMJHp8caQCMg